Childhood cancer treatments can accelerate biological aging, increasing risks for long-term health issues like heart disease and hypertension. Epigenetic age acceleration measures the difference ...

Cognitive sequelae in breast cancer survivorship may reflect treatment- and stress-related acceleration of biologic aging, creating interindividual variability in response to supportive aerobic ...

Worries have persisted that cancer survivors in remission might face increased recurrence risk when treated with biologic drugs for autoimmune disease. This Danish study of rheumatoid arthritis ...

On November 20th, Jazz Pharmaceuticals announced that the FDA has approved ZIIHERA® (zanidatamab-hrii) on an accelerated basis for the treatment of adults with previously treated, unresectable or ...

The US Food and Drug Administration (FDA) has approved more than 23,000 prescription drugs, with many more in development. Increasingly, therapeutic manufacturers are discovering that the key to ...

Not long ago, cancer treatment was often based primarily on where a cancer originated in the body. A patient with lung cancer ...

A Roche drug that is one of the company’s top cancer products is expanding to autoimmune disease with a new FDA approval in lupus nephritis. The intravenously infused drug, Gazyva, may now be used to ...

Scientists are uncovering evidence that the timing of cancer treatment could play a crucial role in its success. Research into circadian rhythms and cancer chronotherapy suggests treatments such as ...

Rheumatoid arthritis (RA) patients in Denmark with a history of solid tumor cancers, now in remission, faced no greater likelihood of cancer relapse when they were treated with biologic agents, ...